Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.

Daisuke HayakawaFumiyuki TakahashiYoichiro MitsuishiKen TajimaMoulid HidayatWira WinardiHiroaki IharaKoichiro KanamoriNaohisa MatsumotoTetsuhiko AsaoRyo KoTakehito ShukuyaKazuya TakamochiTakuo HayashiYoshiyuki SueharaIkuko Takeda NakamuraToshihide UenoShinji KohsakaHiroyuki ManoKazuhisa Takahashi

Published in: Thoracic cancer (2019)

IGF1R activation might be one of the mechanisms of osimertinib resistance. A combination therapy with osimertinib and an IGF1R inhibitor might be an optimal approach for overcoming the acquired resistance to osimertinib induced by IGF1R activation.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
advanced non small cell lung cancer
combination therapy
growth hormone
binding protein
tyrosine kinase
signaling pathway